Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Accured Expenses (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Change in Accured Expenses for 11 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 78.99% year-over-year to $3.1 million, compared with a TTM value of -$764000.0 through Dec 2025, down 105.23%, and an annual FY2025 reading of -$764000.0, down 105.23% over the prior year.
  • Change in Accured Expenses was $3.1 million for Q4 2025 at Spyre Therapeutics, down from $4.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $14.9 million in Q4 2024 and bottomed at -$15.8 million in Q2 2024.
  • Average Change in Accured Expenses over 5 years is $386900.0, with a median of $452500.0 recorded in 2021.
  • Peak annual rise in Change in Accured Expenses hit 1768.46% in 2024, while the deepest fall reached 849.0% in 2024.
  • Year by year, Change in Accured Expenses stood at $455000.0 in 2021, then decreased by 1.1% to $450000.0 in 2022, then tumbled by 298.0% to -$891000.0 in 2023, then skyrocketed by 1768.46% to $14.9 million in 2024, then crashed by 78.99% to $3.1 million in 2025.
  • Business Quant data shows Change in Accured Expenses for SYRE at $3.1 million in Q4 2025, $4.4 million in Q3 2025, and -$2.3 million in Q2 2025.